

(19) World Intellectual Property Organization International Bureau



(43) International Publication Date  
1 September 2005 (01.09.2005)

PCT

(10) International Publication Number  
WO 2005/079830 A1

(51) International Patent Classification<sup>7</sup>: A61K 38/08, 38/06, 38/07, 47/42, 51/08, 35/12, C12Q 1/02, A61P 25/28, 3/10

(21) International Application Number:  
PCT/CA2005/000247

(22) International Filing Date: 22 February 2005 (22.02.2005)

(25) Filing Language: English

(26) Publication Language: English

(30) Priority Data:  
60/546,186 23 February 2004 (23.02.2004) US

(71) Applicant and

(72) Inventor: FRASER, Paul [CA/CA]; 1 Mossom Place, Toronto, Ontario M6S 1G4 (CA).

(74) Agents: NADOR, Anita et al.; 66 Wellington Street West, Suite 4700, P.O. Box 48, Toronto Dominion Bank Tower, Toronto, Ontario M5K 1E6 (CA).

(81) Designated States (unless otherwise indicated, for every kind of national protection available): AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW.


(84) Designated States (unless otherwise indicated, for every kind of regional protection available): ARIPO (BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European (AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LT, LU, MC, NL, PL, PT, RO, SE, SI, SK, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG).

Published:

— with international search report

[Continued on next page]

(54) Title: INHIBITORS OF AMYLOID FIBRIL FORMATION AND USES THEREOF



WO 2005/079830 A1

(57) Abstract: The present invention provides new antifibrillogenic agents and peptides, compositions and cells containing same, compositions that bind to same, effective therapeutics for preventing or delaying the progression of, e.g., Alzheimer's disease and diabetes, methods for optimizing antifibrillogenic agents, and methods of using the antifibrillogenic agents, peptides, compositions, and cells of the invention for detecting and/or inhibiting amyloid fibril formation.



- before the expiration of the time limit for amending the claims and to be republished in the event of receipt of amendments

For two-letter codes and other abbreviations, refer to the "Guidance Notes on Codes and Abbreviations" appearing at the beginning of each regular issue of the PCT Gazette.